newsfilter
← Latest News
GlobeNewswire·

Icosavax Reports First Quarter 2023 Financial Results and Provides Corporate Update

- IVX-A12 (RSV+hMPV) Phase 1 topline interim data expected in 2Q 2023 - - Initiation of IVX-A12 Phase 2 trial expected in 2H 2023 - - Cash and cash equivalents, restricted cash, and short-term investments of $197.7M at